Medtronic (MDT) closed at $94.76 on Oct 16, 2026, down 0.7% on the day. The stock is up 2.1% over the past month, up 13.8% over three months, down 1.4% year to date and down 0.6% over the past year. It trades 10.9% below its 52-week high of $106.33 and 29.3% above its 52-week low of $73.31. The close sits above its 50-day moving average ($90.89) and above its 200-day moving average ($88.30).
NextPick tracks MDT in its Medical Devices basket alongside ABT, ISRG, SYK, BSX and BDX. As of Oct 16, 2026, the basket's money-flow score is 15 (weak inflow), and the basket is up 4.5% over five sessions. Over the past month MDT ranks 8th of 13 basket members by price change.
Over its last 8 reports the stock moved an average of 3.8% on the first trading day after earnings, beating the options-implied move in 3 of 8.
MDT options were pricing 29% at-the-money implied volatility on Oct 7, 2026, an IV rank of 69 over the past year.
Over the last 8 reports, MDT moved an average of 3.8% on the first trading day after earnings. The move beat the options-implied move in 3 of 8 reports.
Yes — the Oct 16, 2026 close of $94.76 is 7.3% above the 200-day average of $88.30.
MDT closed 10.9% below its 52-week high of $106.33.
NextPick groups MDT with ABT, ISRG, SYK, BSX and BDX in its Medical Devices basket.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps an
